利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

166 条记录 (耗时 0.02 秒)

    Composition of positive and negative contrast agents for electron spin resonance enhanced magnetic resonance imaging
    1.
    发明授权
    Composition of positive and negative contrast agents for electron spin resonance enhanced magnetic resonance imaging 失效
    用于电子自旋共振增强磁共振成像的正和负对比剂的组成

    公开(公告)号：US5314681A

    公开(公告)日：1994-05-24

    申请号：US34662

    申请日：1993-03-22

    申请人： Ib Leunbach ,  Klaes Golman ,  Jo Klaveness

    发明人： Ib Leunbach ,  Klaes Golman ,  Jo Klaveness

    IPC分类号： G01R33/28 ,  G01R33/62 ,  A61B5/055 ,  A61K31/40 ,  A61K31/445 ,  G01V3/00

    CPC分类号： G01R33/5601 ,  G01R33/62 ,  Y10S436/806 ,  Y10S514/836 ,  Y10T436/24

    摘要： The invention relates to a modification of electron spin resonance enhanced magnetic resonance imaging (ESREMRI) in which two magnetically responsive materials (contrast agents) are introduced into the sample being investigated, one contrast agent serving as an ESREMRI free induction decay signal enhancing agent and the other as enhancement suppressing agent. In this way, image contrast may be enhanced further for regions in which the suppressing agent distributes poorly or not at all or which the suppressing agent reaches at a later time than the enhancing agent.

    摘要翻译： 本发明涉及电子自旋共振增强磁共振成像（ESREMRI）的修改，其中将两种磁响应材料（造影剂）引入正在研究的样品中，一种造影剂用作无ESREMRI的感应衰变信号增强剂， 其他作为增强抑制剂。 以这种方式，对于抑制剂分布不良或根本不分离的区域或抑制剂在比增强剂更迟的时间达到的区域，图像对比度可以进一步增强。

    USE OF PARTICULATE CONTRAST AGENTS IN DIAGNOSTIC IMAGING FOR STUDYING PHYSIOLOGICAL PARAMATERS
    8.
    发明申请
    USE OF PARTICULATE CONTRAST AGENTS IN DIAGNOSTIC IMAGING FOR STUDYING PHYSIOLOGICAL PARAMATERS 审中-公开
    用于研究生理参数的诊断成像中的粒子对比剂

    公开(公告)号：US20090191131A1

    公开(公告)日：2009-07-30

    申请号：US12354275

    申请日：2009-01-15

    申请人： Sigrid Lise Fossheim ,  Jo Klaveness ,  Atle Bjornerud ,  Pal Rongved ,  Klaes Golman ,  Roald Skurtveit

    发明人： Sigrid Lise Fossheim ,  Jo Klaveness ,  Atle Bjornerud ,  Pal Rongved ,  Klaes Golman ,  Roald Skurtveit

    IPC分类号： A61K49/18 ,  A61K49/12

    CPC分类号： A61B5/01 ,  A61B5/055 ,  A61B5/416 ,  A61B5/4519 ,  A61B8/481 ,  A61K49/1812 ,  A61K49/223

    摘要： The present invention relates to a method of imaging of an animate human or non-human animal body, which method comprises: administering parenterally to said body a particulate material comprising a matrix or membrane material and at least one contrast generating species, which matrix or membrane material is responsive to a pre-selected physiological parameter whereby to alter the contrast efficacy of said species in response to a change in the value of said parameter; generating image data of at least part of said body in which said species is present; and generating therefrom a signal indicative of the value or variation of said parameter in said part of said body. The invention also relates to contrast media for imaging a physiological parameter.

    摘要翻译： 本发明涉及一种对人或非动物体动物进行成像的方法，该方法包括：向所述身体肠胃外给予包含基质或膜材料和至少一种对比生成物质的颗粒材料，所述物质或基质或膜 材料响应于预先选择的生理参数，从而响应于所述参数的值的变化来改变所述物种的对比效能; 生成存在所述物种的所述身体的至少一部分的图像数据; 以及由此生成指示所述身体的所述部分中的所述参数的值或变化的信号。 本发明还涉及用于对生理参数进行成像的造影剂。

    Bismuth compounds
    9.
    发明授权
    Bismuth compounds 失效
    铋化合物

    公开(公告)号：US06303101B1

    公开(公告)日：2001-10-16

    申请号：US09473100

    申请日：1999-12-28

    申请人： Jo Klaveness ,  Arne Berg ,  Torsten Almen ,  Klaes Golman ,  Michael Droege ,  Shi-bao Yu

    发明人： Jo Klaveness ,  Arne Berg ,  Torsten Almen ,  Klaes Golman ,  Michael Droege ,  Shi-bao Yu

    IPC分类号： A61K4900

    CPC分类号： A61K49/04 ,  A61K49/0433 ,  C07F9/94

    摘要： The use in diagnostic imaging, in particular X-ray, MRI, ultrasound and scintigraphy, of contrast agents comprising bismuth clusters and/or organic bismuth compounds, and contrast media containing such bismuth compounds. The bismuth compounds are also useful in therapy, in particular as antimicrobial agents and antiulcer agents. Novel bismuth compounds are also disclosed.

    摘要翻译： 用于包含铋簇和/或有机铋化合物的造影剂的诊断成像，特别是X射线，MRI，超声和闪烁扫描，以及含有这种铋化合物的造影剂。 铋化合物也可用于治疗，特别是抗微生物剂和抗溃疡剂。 还公开了新颖的铋化合物。

    Use of aminolevulinic acid and derivatives thereof
    10.
    发明授权
    Use of aminolevulinic acid and derivatives thereof 有权
    氨基乙酰丙酸及其衍生物的应用

    公开(公告)号：US08759396B2

    公开(公告)日：2014-06-24

    申请号：US12523048

    申请日：2008-01-11

    申请人： Hans Christian Wulf ,  Aslak Godal ,  Jo Klaveness

    发明人： Hans Christian Wulf ,  Aslak Godal ,  Jo Klaveness

    IPC分类号： A01N37/12 ,  A61N1/30

    CPC分类号： A61K41/0061 ,  A61K31/221 ,  A61N5/062

    摘要： The invention provides the use of a photosensitizer which is 5-aminolevulinic acid (5-ALA) or a derivative (e.g. an ester) of 5-ALA, or a pharmaceutically acceptable salt thereof, in the manufacture of a composition for use in methods of photodynamic therapy (PDT) on an animal, wherein said PDT comprises: (a) administering to said animal a composition comprising said photosensitizer; and (b) photoactivating said photosensitizer, and wherein side-effects (e.g. pain and/or erythema) of said PDT are prevented or reduced by use of one or more of (i)-(iv): (i) said composition comprises said photosensitizer in a concentration of less than 10% wt (e.g. 0.5 to 8% wt), (ii) said composition is administered for less than 2 hours (e.g. 30 minutes to 90 minutes) prior to said photoactivation, (iii) said photoactivation is carried out with a light source having a fluence rate of less than 50 mW/cm2 (e.g. 5 to 40 mW/cm2), (iv) said photoactivation is carried out with sunlight. Preferably, side-effects of PDT are prevented or reduced by using (iii) or (iv) in combination with (i) and/or (ii).

    摘要翻译： 本发明提供了5-氨基乙酰丙酸（5-ALA）或5-ALA衍生物（例如酯）或其药学上可接受的盐的光敏剂在制备用于 光动力疗法（PDT），其中所述PDT包括：（a）向所述动物施用包含所述光敏剂的组合物; 和（b）光活化所述光敏剂，并且其中通过使用（i） - （iv）中的一种或多种来防止或减少所述PDT的副作用（例如疼痛和/或红斑）：（i）所述组合物包含 浓度小于10％wt（例如0.5至8％wt）的光敏剂，（ii）所述组合物在所述光活化之前施用少于2小时（例如30分钟至90分钟），（iii）所述光活化是 用光通量小于50mW / cm2（例如5〜40mW / cm2）的光源进行，（iv）所述的光活化是在太阳光下进行的。 优选地，通过使用（iii）或（iv）与（i）和/或（ii）组合来防止或减少PDT的副作用。